THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER

Disclosed are compounds, compositions and methods for treating and/ or ameliorating diseases, syndromes, disorders, or conditions associated with AR mutant receptors linked to castration-resistant prostate cancer, in a subject, including a mammal and/or human, in need thereof, who has demonstrated r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Gilles C. BIGNAN
Format: Patent
Sprache:eng ; spa
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Gilles C. BIGNAN
description Disclosed are compounds, compositions and methods for treating and/ or ameliorating diseases, syndromes, disorders, or conditions associated with AR mutant receptors linked to castration-resistant prostate cancer, in a subject, including a mammal and/or human, in need thereof, who has demonstrated resistance to a first or second generation AR antagonist, comprising, consisting of, and/or consisting essentially of, administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I) Formula (I) wherein R1, G, R10, and R11 are defined herein. Se describen compuestos, composiciones y metodos para tratar y/o mejorar enfermedades, sindromes, trastornos o afecciones asociadas con receptores mutantes del AR vinculados al cancer de prostata resistente a la castracion, en un sujeto, que incluye un mamífero y/o humano, que lo necesita, que ha demostrado resistencia a antagonistas del AR de primera o segunda generacion, que comprende, consiste y/o que consiste esencialmente en administrar a un sujeto que lo necesita una cantidad terapeuticamente eficaz de un compuesto de la Formula (I). (ver fórmula) en donde R1, G, R10 y R11 se definen en la presente descripcion.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_MX2019002097A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>MX2019002097A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_MX2019002097A3</originalsourceid><addsrcrecordid>eNrjZHAP8fD094h0cfQL8ff0U3D0cwnyd3f1UwhydXYNCPEPAoqEOLr7-3kGhwQruAH5IR6uCiFBro4hvq5-IQr-bgrOjn7OrkE8DKxpiTnFqbxQmptByc01xNlDN7UgPz61uCAxOTUvtSTeN8LIwNDSwMDIwNLc0ZgoRQBb0C1Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER</title><source>esp@cenet</source><creator>Gilles C. BIGNAN</creator><creatorcontrib>Gilles C. BIGNAN</creatorcontrib><description>Disclosed are compounds, compositions and methods for treating and/ or ameliorating diseases, syndromes, disorders, or conditions associated with AR mutant receptors linked to castration-resistant prostate cancer, in a subject, including a mammal and/or human, in need thereof, who has demonstrated resistance to a first or second generation AR antagonist, comprising, consisting of, and/or consisting essentially of, administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I) Formula (I) wherein R1, G, R10, and R11 are defined herein. Se describen compuestos, composiciones y metodos para tratar y/o mejorar enfermedades, sindromes, trastornos o afecciones asociadas con receptores mutantes del AR vinculados al cancer de prostata resistente a la castracion, en un sujeto, que incluye un mamífero y/o humano, que lo necesita, que ha demostrado resistencia a antagonistas del AR de primera o segunda generacion, que comprende, consiste y/o que consiste esencialmente en administrar a un sujeto que lo necesita una cantidad terapeuticamente eficaz de un compuesto de la Formula (I). (ver fórmula) en donde R1, G, R10 y R11 se definen en la presente descripcion.</description><language>eng ; spa</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2019</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20190515&amp;DB=EPODOC&amp;CC=MX&amp;NR=2019002097A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25544,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20190515&amp;DB=EPODOC&amp;CC=MX&amp;NR=2019002097A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Gilles C. BIGNAN</creatorcontrib><title>THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER</title><description>Disclosed are compounds, compositions and methods for treating and/ or ameliorating diseases, syndromes, disorders, or conditions associated with AR mutant receptors linked to castration-resistant prostate cancer, in a subject, including a mammal and/or human, in need thereof, who has demonstrated resistance to a first or second generation AR antagonist, comprising, consisting of, and/or consisting essentially of, administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I) Formula (I) wherein R1, G, R10, and R11 are defined herein. Se describen compuestos, composiciones y metodos para tratar y/o mejorar enfermedades, sindromes, trastornos o afecciones asociadas con receptores mutantes del AR vinculados al cancer de prostata resistente a la castracion, en un sujeto, que incluye un mamífero y/o humano, que lo necesita, que ha demostrado resistencia a antagonistas del AR de primera o segunda generacion, que comprende, consiste y/o que consiste esencialmente en administrar a un sujeto que lo necesita una cantidad terapeuticamente eficaz de un compuesto de la Formula (I). (ver fórmula) en donde R1, G, R10 y R11 se definen en la presente descripcion.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2019</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHAP8fD094h0cfQL8ff0U3D0cwnyd3f1UwhydXYNCPEPAoqEOLr7-3kGhwQruAH5IR6uCiFBro4hvq5-IQr-bgrOjn7OrkE8DKxpiTnFqbxQmptByc01xNlDN7UgPz61uCAxOTUvtSTeN8LIwNDSwMDIwNLc0ZgoRQBb0C1Q</recordid><startdate>20190515</startdate><enddate>20190515</enddate><creator>Gilles C. BIGNAN</creator><scope>EVB</scope></search><sort><creationdate>20190515</creationdate><title>THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER</title><author>Gilles C. BIGNAN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_MX2019002097A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; spa</language><creationdate>2019</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>Gilles C. BIGNAN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Gilles C. BIGNAN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER</title><date>2019-05-15</date><risdate>2019</risdate><abstract>Disclosed are compounds, compositions and methods for treating and/ or ameliorating diseases, syndromes, disorders, or conditions associated with AR mutant receptors linked to castration-resistant prostate cancer, in a subject, including a mammal and/or human, in need thereof, who has demonstrated resistance to a first or second generation AR antagonist, comprising, consisting of, and/or consisting essentially of, administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I) Formula (I) wherein R1, G, R10, and R11 are defined herein. Se describen compuestos, composiciones y metodos para tratar y/o mejorar enfermedades, sindromes, trastornos o afecciones asociadas con receptores mutantes del AR vinculados al cancer de prostata resistente a la castracion, en un sujeto, que incluye un mamífero y/o humano, que lo necesita, que ha demostrado resistencia a antagonistas del AR de primera o segunda generacion, que comprende, consiste y/o que consiste esencialmente en administrar a un sujeto que lo necesita una cantidad terapeuticamente eficaz de un compuesto de la Formula (I). (ver fórmula) en donde R1, G, R10 y R11 se definen en la presente descripcion.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; spa
recordid cdi_epo_espacenet_MX2019002097A
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T06%3A04%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Gilles%20C.%20BIGNAN&rft.date=2019-05-15&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EMX2019002097A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true